Skip to main content
EJNMMI Research
Fig. 6 | EJNMMI Research

Fig. 6

From: Indium-111-labeled CD166-targeted peptide as a potential nuclear imaging agent for detecting colorectal cancer stem-like cells in a xenograft mouse model

Fig. 6

The CD166 imaging in tumors and organs of CRC xenograft mice. a The CD166 imaging of both CD166+HCT15 and CD166−HCT15 xenograft model. Both CD166+HCT15 and CD166−HCT15 cells were subcutaneously inoculated into the right flank of nude mice for establishing CD166 high- and non-expressed xenograft model, respectively. The Cy5.5-conjugated CD166tp-G18C was intravenously injected into both xenograft mice for 6 h and observed by in vivo imaging system. b The distribution of CD166 imaging in various organs and tumor tissue of CD166+HCT15 xenograft mice. The top panel presented the CD166 imaging in various organs. The button panel presented the quantitation of fluorescent signals. Data are presented as mean ± SD (n = 3). *P < 0.05, versus other organs. c The protein expressions of CD166 in tumors and various organs of CD166+HCT15 xenograft mice. d The CD166 expressions in tumors of both CD166+HCT15 and CD166−HCT15 xenograft mice. In c and d, protein expressions were determined by Western blotting and quantified by densitometry and normalized by GAPDH levels. In c, data are presented as mean ± SD (n = 3). *P < 0.05, versus other organs. In d, data are presented as mean ± SD (n = 3). *P < 0.05, versus 100 mm3 (CD166−HCT15); #P < 0.05, versus 150 mm3 (CD166−HCT15)

Back to article page